Michelle Dawson posts

Post published on Twitter/X on 15 Jun 2022 14:47

Twitter/X Clinical trial clinicaltrials.gov Question asked by Dawson in the post External link integrated into the post Autism terms

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Quadrant Biosciences Inc., University of California, Irvine, Holland Bloorview Kids Rehabilitation Hospital, Children's Hospital of Philadelphia, MetroHealth Medical Center, University of Rochester, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, et al. (2022). Validation of a Salivary miRNA Diagnostic Test for ASD. ClinicalTrials.gov. Quadrant Biosciences Inc..

Publication date
16 Mar 2022
Identifier
NCT05418023
Authors
Quadrant Biosciences Inc., University of California, Irvine, Holland Bloorview Kids Rehabilitation Hospital, Children's Hospital of Philadelphia, MetroHealth Medical Center, University of Rochester, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, University of Pittsburgh, University of Massachusetts, Worcester, Children's Hospital Los Angeles, Prisma Health-Upstate, University of Virginia, State University of New York - Upstate Medical University, Rush University, Seattle Children's Hospital, Drexel University, Emory University
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Quadrant Biosciences Inc.
Metadata source
clinicaltrials.gov

Abstract

This study involves sample collection to identify biomarkers relating to Autism Spectrum Disorder(ASD) in the saliva of children who are between the ages of 18 months to 6 years and 11 months. Participants will at each timepoint have a non-invasive saliva swab collected and complete a brief demographic and medical history questionnaire as well. Children in the pediatric/provider setting who will receive a referral for an ASD diagnosis because they were determined to have a suspicion of developing ASD will be enrolled in the study. Children will also be enrolled in the specialist evaluation setting where they will receive a DSM-5 diagnosis. A subset of both enrollment cohorts will also be followed up with at a third time point in which their diagnosis will be confirmed, and information about any ongoing treatment will be gathered.